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Background: Genetic studies of salivary gland neoplasms
were mainly focused on chromosomal changes, and some
specific patterns of chromosome translocations have been
described. However, molecular alterations, in particular the
role of HER-2/H-ras/c-myc signalling cascade in pleomor-
phic adenoma pathogenesis (PA), are less well characterized.
In addition, data on single nucleotide polymorphisms (SNPs)
as potential susceptibility factors for PA development are also
quite scarce. 
Methods: Mutational analyses were performed by means of
real-time PCR (HER-2 and c-myc amplification analysis),
PCR–SSCP and sequencing (H-ras point mutation detec-
tion). Polymorphisms analysis was performed by PCR–RFLP
(survivin and MMP-9 genes). 
Results: Amplification of HER-2 and c-myc has been found
in 13% and 9% of PA cases respectively. Point mutations in
H-ras codons 12/13 have been detected in 17% of PAs. No
correlation could be established between these alterations
and clinical characteristics of PAs, whereas they might play
a role in a subset of malignant salivary gland tumours. As
for survivin -31 G/C polymorphism, C allele carriers had a 
4-fold decrease of the risk of developing PA (p=0.05).
Carriers of the variant allele T of the -1562C/T SNP in
MMP-9 gene had a 4-fold increase of the risk of developing
PA (p<0.001). 
Kratak sadr`aj
Uvod: U ispitivanjima mehanizama nastanka tumora plju-
va~nih `lezda uglavnom dominiraju citogeneti~ke studije, pa
su tako detektovane i opisane razli~ite hromozomske tran s -
lokacije sa specifi~nim obrascem javljanja. Me|utim, mole -
ku larne promene u ovim tumorima i dalje su relativno slabo
poznate, a pogotovo je malo podataka o potencijalnom
zna~aju signalnog puta HER-2/H-ras/c-myc u razvoju i pro-
gresiji pleomorfnih adenoma (PA). Tako|e, retki su i podaci
o polimorfizmima pojedina~nog nukleotida (SNP) kao fakto-
ra predispozicije za nastanak PA.
Metode: Analize somatskih mutacija ura|ene su metodama
real-time PCR (analiza amplifikacije HER-2 i c-myc), PCR–SSCP
i sekvenciranja (detekcija ta~kastih mutacija u H-ras). Ana liza
polimorfizama pojedina~nih nukleotida (SNP) vr{e na je prime -
nom metode PCR–RFLP (u genima za survivin i MMP-9).
Rezultati: Amplifikacija gena HER-2 detektovana je u 13%,
c-myc u 9% a ta~kaste mutacije u kodonima 12/13 H-ras
gena u 17% uzoraka. Nije ustanovljena veza izme|u ovih
promena i klini~kih odlika adenoma. Na malom uzorku kar-
cinoma, pokazano je da je amplifikacija HER-2 povezana sa
recidivima tumora. Nosioci C alela u -31G/C SNP gena za
survivin imaju ~etiri puta manji rizik od nastanka PA
(p=0,05), dok nosioci varijantnog alela T kod -1562 C/T
SNP u MMP-9 genu imaju ~etiri puta ve}i rizik da obole od
PA u odnosu na kontrolu (p<0,001). 
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Introduction
Salivary gland (SG) tumours are a highly hetero-
geneous group of tumours and include more than 35
histological subtypes, from benign adenomas to high-
grade carcinomas. 
Pleomorphic adenoma (PA) is the most com-
mon salivary gland tumour representing about a half
of all salivary gland neoplasms and 65% of parotid
gland tumours (1–3). Pleomorphic adenoma (PA) is a
benign mixed salivary gland tumour, associated with
abnormal karyotypes in up to 70% of cases, with non-
random involvement of 8q12, the locus of the pleo-
morphic adenoma (PLAG1) gene.
The vast majority of pleomorphic adenomas
occur in the parotid glands, but they can also be
found in the submandibular glands, sublingual
glands, or small salivary glands. They mostly arise
between the ages of 30 and 60 years and are more
commonly found in females than in males (4).
Histologically, they are characterized by variable pat-
terns formed by both epithelial and myoepithelial
cells in a mucoid/myxoid, chondroid, or hyalinised
stroma. The main therapy is surgical removal of the
tumour with surrounding salivary gland tissue. Some
2 to 17% of all pleomorphic adenomas tend to the
undergo a malignant transformation, giving rise to
the so-called »carcinoma ex pleomorphic adenoma«
(CXPA) (3–5). 
Previous studies of the pathogenesis of pleomor-
phic adenomas were mainly focused on chromosom -
al changes and have shown that PA are characterized
by highly specific patterns of chromosome transloca-
tions, preferentially affecting the DNA-binding tran-
scription factor genes PLAG1 and HMGA2 (6–8).
Molecular changes in PA, however, are not well char-
acterized and, also, very little is known about the
genetic events leading to their transformation into
carcinomas (9–13). 
Activation of oncogenes, when coupled with
inactivation of tumour suppressor genes, leads to
uncontrolled cell proliferation. One of the commonly
activated signalling pathways in tumorigenesis is the
HER-2/H-ras/c-myc pathway.
Human epidermal growth factor receptor-2
(HER-2, also known as c-erbB-2 or neu) gene is a
proto-oncogene located on chromosome 17 and it
encodes a 185-kd transmembrane tyrosine kinase
receptor (14). HER-2 is a member of the epidermal
growth factor receptor family and is recognized as a
key oncogene in several malignancies (15). Amplifi -
cation of the HER-2 gene and overexpression of the
HER-2 protein have been observed in various solid
tumours (16–18).
H-ras oncogene, located on chromosome 11, is
functionally related to HER-2. The protein product
of H-ras oncogene – p21, transmits signals via
Raf/MAPK signalling cascades to various transcrip-
tion factors (19). H-ras is usually activated by point
mutations in codons 12, 13 and 61. 
The c-myc oncogene encodes a transcription
factor with an essential role in cell proliferation, cell
growth, differentiation and apoptosis (20, 21). Its
protein product controls the expression of 10–15% of
all mammalian genes, weather as an activator or as a
repressor (22). The most common c-myc aberration
leading to its activation in solid tumours is gene
amplification (23). It is also functionally related to
HER-2 and H-ras. To date, little is known about the
involvement of HER-2/H-ras/c-myc signalling cascade
in the development of PAs and about its possible
prognostic significance in both PAs and CXPAs (10,
24, 25). 
PA, like the vast majority of tumours, is a multi-
factorial, polygenic disease, and heredity may repre-
sent an important factor in its development. Although
gene polymorphisms are an expression of normal
variations in the hereditary basis, their effect on the
phenotype is interesting, especially the association
with susceptibility to certain diseases (26). Specif i -
cally, predisposition to PA could be modulated,
among others, by functional polymorphisms in the
genes related to mechanisms, more or less intrinsic to
salivary gland tumorigenesis. 
Survivin, a key regulator of mitosis and program -
med cell death, has been shown to play a prominent
role in the promotion of tumorigenesis. Changes in its
expression may be the consequence of gene amplifi-
cation, hypomethylation, etc. In some instances, they
may be due to a common -31 G/C single nucleotide
polymorphism (SNP) at the CDE/CHR repressor bind-
ing motif of the survivin gene promoter (27).
Consequently, functional polymorphisms influencing
survivin expression may thus be considered as risk
factors for carcinogenesis (28). 
Conclusions: A longer follow-up of PA patients harbouring
mutations could uncover a prognostic role of HER-2 and c-
myc amplification as predictors of adenoma transformation
into carcinoma. Both survivin and MMP-9 promoter poly-
morphisms represent susceptibility factors for the develop-
ment of PAs in the Serbian population.
Keywords: pleomorphic adenoma, HER-2, c-myc, sur-
vivin, MMP-9
Zaklju~ak: Du`im pra}enjem pacijenata sa PA mogla bi da
se ustanovi prognosti~ka uloga HER-2 i c-myc amplifikacija
kao indikatora za transformaciju adenoma u karcinom.
Polimorfizmi u promotorima gena za survivin i MMP-9 pred-
stavljaju modulatore rizika za razvoj pleomorfnih adenoma u
srpskoj populaciji.
Klju~ne re~i: pleomorfni adenom, HER-2, c-myc, sur-
vivin, MMP-9
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Matrix metalloproteinases (MMPs) are zinc-
dependent endopeptidases subdivided into 5 major
groups, capable of degrading almost all components
of the extracellular matrix including interstitial and
basement membrane collagens, fibronectin, laminin
and proteoglycan core protein. They are involved in
connective tissue remodelling and degradation.
MMP 9 contributes to carcinogenesis, tumour
growth, invasion and angiogenesis. A SNP in the pro-
moter region of the MMP 9 gene (-1562 C/T) may
influence tumour occurrence and progression via
modifying mRNA transcription and protein expres-
sion. The C-T base substitution leads to increased
transcriptional activity and genotypes with a T allele
(CT, TT) have higher enzymatic activity (29).
The aims of this study were to: 1) determine the
importance of mutations in HER-2, H-ras and c-myc
genes in pleomorphic adenoma pathogenesis; 2)
establish the role of SNPs in the survivin and MMP 9
genes as putative susceptibility factors for pleomorphic
adenoma development in the Serbian population. 
Material and Methods 
Samples
In total, 54 PA and 6 CXPA samples from
patients treated at the Clinic of Maxillofacial Surgery,
School of Dental Medicine, University of Belgrade
(2007–2010), were included in this study. The study
was performed in compliance with the Declaration of
Helsinki ethical guidelines and approved by the Ethics
Committee of the home institution. All participants
have signed an informed consent form. The DNA was
extracted from formalin-fixed, paraffin-embedded
samples. Deparaffinization was carried out by two
immersions in xylene followed by rehydration in
absolute and 70% ethanol. Total genomic DNA was
obtained using a standard phenol/chloroform extrac-
tion protocol. For the association study, a larger num-
ber of both PA and control DNA samples was used (74
PAs and 127 controls for survivin SNP analysis and 51
PAs and 101 controls for MMP-9 SNP analysis).
Real–time PCR
A real–time polymerase chain reaction (qPCR) –
comparative Ct method of quantitation (DDCt) was
performed using MaximaTM SYBR Green qPCR
Master Mix(2X) (MBI, Fermentas, Vilnius, Lithuania).
Primer sequences were HER-2: F 5’CCTCTGACGTC-
CATCATCT3’, R 5’ATCTTCTGCTGCCGTCGTT3’; c-
myc: F 5’GCTCCAAGACGTTGTGTGTTCG3’, R
5’GGAAGGACTATCCTGCTGCCAA3’. A single-copy
gene encoding dopamine D2 receptor (D2R) was
used as a reference gene in this study. Primer se -
quences for the D2R gene were: F 5’ CCACT-
GAATCTGTCCTGGTATG 3’, R 5’ GTGTGGCATAG-
TAGTTGTAGTGG 3’. qPCR reactions for all genes for
each sample were carried out in duplicate, using 20 ng
DNA as a template. To confirm the specificity of the
amplified product, we performed the melting curve
analysis in each case. The DDCt was calculated se p -
arately for HER-2, c-myc and the D2R gene and the
amplification levels of each sample were normalized
against D2R as a reference gene. A gene dose great -
er than 2.5 was considered amplified.
Polymerase chain reaction–single strand 
conformation polymorphism (PCR–SSCP)
The screening for the presence of the most
common mutations in codons 12 and 13 of the H-ras
oncogene was done using PCR amplification followed
by SSCP analysis. PCR reaction was performed in a
volume of 25 mL reaction mixture containing 300 ng
of genomic DNA  and 200 nM of the following primer
pair: F 5’ATGACGGAATATAAGCTGGT 3’ and  R 5’
CGCCAGGCTCACCTCTATA 3’.
PCR conditions were: initial denaturation step at
95 °C (3 min), followed by 35 cycles at 95 °C (30 s),
50 °C (30 s), 72 °C (30 s) and final extension at 72 °C
(7 min). The amplified product of 123 bp was visual-
ized using 8% polyacrylamide gel electrophoresis and
ethidium bromide staining. For further SSCP analysis,
5 mL of PCR product were mixed with 10 mL of load-
ing dye (95% formamide, 20 mmol/L EDTA, 0.05
xylene cyanol, 0.05% bromophenol blue). The sam-
ples were denaturated  in the thermal cycler by heat-
ing to 96°C for 8 min, then loaded onto 10% non-
denaturating polyacrylamide gel. Gels were stained
with 2% AgNO3. The presence of mobility shift of
bands was an indication of mutation. A PCR product
of a sample obtained from the blood of a healthy sub-
ject was used as a negative control. 
To maximize the accuracy, each sample was test-
ed at least twice by separated PCR reactions and SSCP
runs. In order to confirm the results of PCR–SSCP, DNA
samples were sequenced commercially.
Survivin-31 G/C (rs9904341) genotyping 
Survivin promoter polymorphism at position -31
was determined by polymerase chain reaction–restric-
tion fragment length polymorphism (PCR–RFLP).
Primers F 5’-AAGAGGGCGTGCGCTCCCGACA-3’
and R 5’-GAGATGCGGTGGTCCTTGAGAAA-3’ ge n -
erated a fragment surrounding -31 G/C SNP of 151
bp. PCR was performed in a total volume of 20 mL
containing 2 mL of 10 × PCR buffer (MBI, Fermentas,
Vilnius, Lithuania), 1.5 mmol/L of MgCl2, 0.2
mmol/L dNTPs, 0.375 mmol/L of each primer, 200
ng of genomic DNA and 1 unit of Taq DNA poly-
merase (MBI, Fermentas, Vilnius, Lithuania). The
amplification conditions for -31 G/C were as follows:
initial denaturation at 95 for 5 minutes, followed by
35 cycles consisting of denaturation at 94 °C for 45 s,
annealing at 60 °C for 45 s, elongation at 72 °C for 1
min, and a final elongation at 72 °C for 10 min. 
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The amplified fragment was digested with 5
units of Msp I (MBI, Fermentas, Vilnius, Lithuania),
resulting in products of 151 base pairs (bp) for the
GG genotype, two fragments of 90 and 61 bp for the
CC genotype and three fragments of 151, 90 and 61
bp for the CG genotype. 
MMP-9 -1562 C/T (rs3918242) genotyping
The sequence surrounding the SNP position in
the MMP-9 gene promoter was amplified using the
primer pair: F 5’-GCCTGGCACATAGTAGGCCC-3’
and R 5’-CTTCCTAGCCAGCCGGCATC -3’. PCR was
carried out in a total volume of 25 mL, containing 300
ng genomic DNA, 10 mmol/L Tris-HCl (pH 8.3), 50
mmol/L KCl, 1.5 mmol/L MgCl2, 1 mmol/L of each
primer, 200 mmol/L each dATP, dCTP, dGTP and
dTTP, and 2.5 U Taq DNA polymerase (Amersham
Pharmacia Biotech AB, Uppsala, Sweden). The solu-
tion was incubated for 3 min at 95 °C, followed by
35 cycles of 1 min at 95 °C, 45 s at 65 °C and 45 s
at 72 °C, with a final extension of 72 °C for 7 min.
Each PCR product was digested with three units
of SphI (MBI, Fermentas, Vilnius, Lithuania) overnight
and the fragments were separated on an 8% polyacryl -
amide gel stained with ethidium bromide. After di -
gestion, wild type homozygotes (CC) showed 1 band
of 435  bp, mutated homozygotes (TT) had 2 bands
(247 and 188 bp) and heterozygotes (CT) had 3
bands (435, 247 and 188 bp). 
Genotypes were confirmed by randomly re-geno -
typing 10% of the samples. There were no discrepan-
cies between the genotypes determined in duplicate.
Statistical analysis
Chi square test was used to determine possible
differences in the genotype and allele frequencies.
The association of -31 survivin and MMP-9 variants
with risk of disease was examined by use of uncondi-
tional logistic regression analysis to calculate odds
ratios (OR) and their 95% confidence intervals (CI). P
values of <0.05 were considered statistically signifi-
cant. 
The expected frequency of survivin and MMP-9
variants in controls was analyzed by the Hardy-Wein -
berg equilibrium test. Calculations were performed
with the statistical package Stata V6.
Results
Mutational analysis
Amplification of HER-2 was identified in 7 out of
54 (13%) cases of PA and in 2 out of 6 (33%) cases
of CXPA. MYC was amplified in 5 out of 54 (9%)
cases of PA and in 2 out of 6 (33%) cases of CXPA. 
H-ras codon 12/13 mutations were found in 9
cases of PA (16.7%) and none of CXPA. Mutational
analysis and epidemiological data are summarized in
Table I. There was no statistically significant difference
between molecular findings in different clinical sub-
groups. SSCP analysis also detected an H-ras codon
27 (His27His) polymorphism in exon, in 19 out of 54
cases (35%). This finding was confirmed by RFLP
(data not shown).
Table I Molecular findings in relation to clinical and epidemiologic data in 54 cases of salivary gland pleomorphic adenoma.









































































The observed genotype frequencies in the case
and control groups were in the Hardy-Weinberg equi-
librium. The genotype and allele frequency distribu-
tion and risk estimates of survivin -31 G/C polymor-
phism are given in Table II. In terms of susceptibility,
individuals homozygous for C have approximately a 
4-fold de crease in the risk for developing PA, com -
pared to GG homozygotes (p=0.05). The C allele
obvio usly exhibits a protective effect in its carriers.
A significant difference in genotype and allele
frequencies was also found between the PA group
and controls for the -1562C>T SNP (p<0.001).
Carriers of the variant allele T had roughly a 4-fold
increase in susceptibility for PA compared to wild type
homozygotes (CC). The observed genotype and allele
frequency distribution and risk estimates are given in
Table II.
Discussion
Though alterations of oncogenes and tumour
suppressor genes have been implicated in the devel-
opment of salivary gland tumours, very little is still
known about the possible role of the HER-2/H-ras/c-
myc signalling cascade in PAs. 
The present study showed that the magnitude of
molecular changes in the HER-2/H-ras/c-myc path-
way was rather modest in PAs and somewhat higher
in carcinomas, though the latter results are not fully
reliable due to the small sample size. Amplification of
HER-2 was identified in 13% cases of PA and in 33%
of CXPA cases. C-myc was amplified in 9% of PAs
and also in 33% of CXPA cases. The gain of genes or
chromosome regions commonly occurs in tumour
cells, but a recent study using FISH did not show evi-
dence of HER-2 gene amplification in benign pleo-
morphic adenomas (30). Nonetheless, HER-2 ampli-
fication has been previously indicated as a common
event in the process of PA transformation into carci-
noma ex pleomorphic adenoma (10). It has also been
shown that HER-2 and TP53 are synergistically
involved in the early stages of malignant transforma-
tion of PA (25, 31). C-myc amplification has previous-
ly been reported in some cases of CXPA, but never in
benign PA (32, 33). In the present study, HER-2 and
c-myc amplification were a rare event, but one cannot
exclude a subgroup of PA in which this signalling cas-
cade is activated. It must be emphasized that HER-2
amplification was often related to recurrences in
malignant tumours. One carcinoma with both genes
amplified was metastatic, though the preceding
benign tumour revealed no amplification of HER-2
nor c-myc oncogenes. Some researchers suggest that
HER-2 plays a role in the progression of carcinoma ex
PA, and that the presence of HER-2 amplification
might be an indicator of poor prognosis, which is cor-
roborated by the present study (34).
Our results on H-ras mutations incidence in PA,
though lower (17%) than the results previously re -
ported for the same population (35%) by Milasin et al.
(35), are not negligible and point to a possible invol -
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Table II Genotype and allele frequencies and logistic regression analysis data for –31 G/C survivin gene and –1562 C/T MMP-9
gene polymorphisms.                                                      
PA – pleomorphic adenoma, OR – odds ratio, CI – confidence interval
Survivin –31 G/C
genotype PA (n=74) Control (n=127) OR 95% CI p
GG 32 (43%) 51 (40%) Reference
GC 40 (54%) 63 (50%) 1.01 0.56–1.83 0.54
CC 2 (3%) 13 (10%) 0.25 0.05–1.16 0.050*
GC + CC 42 (57%) 76 (60%) 0.88 0.49–1.57 0.388
allele
G 0.70 0.64 Reference
C 0.30 0.36 0.76 0.42–1.38 0.23





(n=101) OR 95% CI p
CC 27 (53%) 83 (82%) Reference
CT 22 (43%) 17 (17%) 3.98 1.85–8.57 <0.001*
TT 2 (4%) 1 (1%) 6.1 0.54–70.50 0.16
CT + TT 24 (47%) 18 (18%) 4.1 1.94–8.67 <0.001*
allele
C 76 (75%) 183 (91%) Reference 
T 26 (25%) 19 (9%) 3.37 1.48–7.66 0.002*
vement of this specific molecular change in the
pathogenesis of a particular PA subgroup. Conversely,
Augello et al, (11) who detected a mutated H-ras
gene in only 4% of PAs, concluded that Ras mutations
are irrelevant in PA pathogenesis. Though none of
the gene alterations could be related to the clinical
characteristics of PAs, a potential implication of these
mutations in malignant transformation of adenomas
into carcinomas cannot be excluded, making essen-
tial an extended follow-up of the patients harbouring
mutations.
Contrasting with oncogene analysis, polymor-
phisms analysis gave more satisfactory results. Only a
few association studies trying to correlate gene poly-
morphisms and risk of PA have been carried out and
none concerning survivin and MMP-9 gene promoter
SNPs.
It was suggested that survivin, a member of IAPs
(Inhibitor of Apoptosis Protein) family which functions
both as a promoter of cell proliferation and inhibitor
of apoptosis is overexpressed in various malignancies,
but also in some benign tumours (36, 37). Our study
indicates that carriers of the C allele have a 4-fold
decrease in PA susceptibility compared to GG homo -
zygotes (p=0.05), i.e. that the C allele has a protec-
tive role. Similar results have already been obtained
for another type of benign tumours in the Serbian
population, the keratocystic odontogenic tumours
(38), as well as in one type of malignancy – Wilm’s
tumours (39).
The SNP –1562 C/T in the promoter of the
MMP-9 gene was shown to upregulate gene tran-
scription, which in turn leads to increased biosynthe-
sis of the enzyme with high potential to degrade the
connective tissue matrix. In the study of Zhang et al.
(40) higher levels of MMP-9 expression have been
ob served in PA, compared to normal salivary gland
tissue, which is in line with our results. Namely, we
observed a 4-fold increase of PA risk in heterozygous
carriers of the variant T allele, which is responsible for
the transcription upregulation, indicating a strong
association of the -1562 single nucleotide polymor-
phism in the MMP-9 gene promoter with the develop-
ment of PA in the Serbian population. 
Despite numerous studies, the natural history of
pleomorphic adenomas, the most common salivary
gland tumors, remains unclear. It seems, however,
that HER-2 amplification emerged as a valid marker
of salivary gland tumour aggressiveness. In addition,
detection of specific polymorphisms might help in
the identification of patients particularly inclined to
develop pleomorphic adenomas.
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